John W. Walsh Alpha-1 Home Infusion Act of 2023

Hozzl · 2024-12-20T09:06:13Z

Explore the details of House Bill 4438 John W. Walsh Alpha-1 Home Infusion Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/20/2024, 9:06 AM

Summary of Bill HR 4438

Bill 118 HR 4438, also known as the John W. Walsh Alpha-1 Home Infusion Act of 2023, aims to improve access to home infusion therapy for individuals with Alpha-1 Antitrypsin Deficiency. This genetic disorder can lead to serious lung and liver complications, and home infusion therapy can help manage symptoms and improve quality of life for patients.

The bill proposes to establish a demonstration program within Medicare to provide coverage for home infusion therapy services specifically for individuals with Alpha-1 Antitrypsin Deficiency. This program would allow patients to receive necessary medications and treatments in the comfort of their own homes, rather than having to travel to a healthcare facility for infusion therapy.

Additionally, the bill includes provisions to ensure that healthcare providers are properly trained and certified to administer home infusion therapy for Alpha-1 patients. This would help ensure the safety and effectiveness of the treatments provided in the home setting. Overall, the John W. Walsh Alpha-1 Home Infusion Act of 2023 seeks to improve access to care and quality of life for individuals with Alpha-1 Antitrypsin Deficiency by expanding coverage for home infusion therapy services through Medicare.

Congressional Summary of HR 4438

John W. Walsh Alpha-1 Home Infusion Act of 2023

This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 4438

Bill HR 4438 is currently in the status of Bill Introduced since June 30, 2023. Bill HR 4438 was introduced during Congress 118 and was introduced to the House on June 30, 2023. Bill HR 4438's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024

Bipartisan Support of Bill HR 4438

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 4438

Primary Policy Focus

Health

Potential Impact Areas

- Cardiovascular and respiratory health

- Genetics

- Health care coverage and access

- Health personnel

- Hereditary and development disorders

- Home and outpatient care

- Medicare

Alternate Title(s) of Bill HR 4438

John W. Walsh Alpha-1 Home Infusion Act of 2023

To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes.